POLBF (Poolbeg Pharma) Dividends per Share: $0.00 (TTM As of Dec. 2025)


What is Poolbeg Pharma Dividends per Share?

Poolbeg Pharma POLBF Dividends per Share is $0.00 as of Dec. 2025. The stock has 1 warning sign investors should review.

Poolbeg Pharma's dividends per share for the six months ended in Dec. 2025 was $0.00. Its dividends per share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.00. Its Dividend Payout Ratio for the six months ended in Dec. 2025 was 0.00. As of today, Poolbeg Pharma's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.

Poolbeg Pharma  (OTCPK:POLBF) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Poolbeg Pharma's Dividend Payout Ratio for the quarter that ended in Dec. 2025 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Dec. 2025 )/ EPS without NRI (Q: Dec. 2025 )
=0/ -0.007
=N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Poolbeg Pharma Dividends per Share Related Terms

Poolbeg Pharma Dividends per Share Historical Data

* Premium members only.

The historical data trend for Poolbeg Pharma's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Poolbeg Pharma Dividends per Share Chart

Poolbeg Pharma Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Dividends per Share
0.00 0.00 0.00 0.00 0.00

Poolbeg Pharma Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Dividends per Share Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

POLBF vs VRTX, REGN, ALNY: Dividends per Share Comparison

For the Biotechnology subindustry, Poolbeg Pharma's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Poolbeg Pharma Dividend Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Poolbeg Pharma's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Poolbeg Pharma's Dividend Yield % falls into.


Poolbeg Pharma Dividends per Share Calculation

Dividends paid to per common share.

Frequently Asked Questions Learn more about Dividends per Share →
What does a Dividends per Share of $0.00 mean?
Poolbeg Pharma (POLBF) has a Dividends per Share of $0.00 as of Dec. 2025. Dividends per share represents the per-share amount paid as dividends. View historical data on Poolbeg Pharma and its competitors.
Is Poolbeg Pharma's Dividends per Share too high?
Poolbeg Pharma's current Dividends per Share is $0.00.
How does Poolbeg Pharma's Dividends per Share compare to VRTX and REGN?
Poolbeg Pharma's Dividends per Share of $0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividends per Share for a Biotechnology company?
A good Dividends per Share depends on the Biotechnology industry context. However, Dividends per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividends per Share mean?
A high Dividends per Share can signal that a stock is expensive relative to its fundamentals. Dividends per share represents the per-share amount paid as dividends. View historical data on Poolbeg Pharma and its competitors. Poolbeg Pharma's current Dividends per Share is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poolbeg Pharma stock overvalued right now?
Poolbeg Pharma (POLBF) has a current Dividends per Share of $0.00. The current Dividends per Share is $0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividends per Share calculated?
Dividends per Share is calculated from a company's financial statements. For Poolbeg Pharma (POLBF), the current Dividends per Share is $0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Poolbeg Pharma Business Description

Other Exchanges POLB:UK7JN:Germany
Address 20 St. Andrew Street, The Clubhouse Holborn, London, GBR, EC4A 3AG
Poolbeg Pharma PLC is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company's main asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). The group is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world's markets. It is focused on partnering its high-value programmes that are targeting large markets and addressing critical unmet medical needs.